http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
PureTech Health Plc (PRTC) Announces Publication of Phase 1 Results for LYT-100
-
PureTech Announces Publication of Phase 1 Results for LYT-100 in the Journal Clinical Pharmacology in Drug Development and Provides Timing Updates
-
PureTech Announces Participation in Two Upcoming Investor Conferences
-
PureTech Presents Clinical Trial Design Supporting Wholly Owned Immuno-Oncology Candidate LYT-200 at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
-
PureTech Health (PRTC) Receives Orphan Drug Designation for Wholly Owned Candidate LYT-200 for the Treatment of Pancreatic Cancer
-
PureTech Receives Orphan Drug Designation for Wholly Owned Candidate LYT-200 for the Treatment of Pancreatic Cancer
-
PureTech Founded Entity Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China
-
PureTech Announces Participation at the Jefferies London Healthcare Conference
-
PureTech Health (PRTC) Notes Publication in Nature’s Scientific Reports Featuring Gelesis Foundational Biomimetic Platform for Treating Obesity and Conditions Related to Diet-Induced Gut Damage
-
PureTech Is Pleased to Note Publication in Nature’s Scientific Reports Featuring the Gelesis Foundational Biomimetic Platform for Treating Obesity and Conditions Related to Diet-Induced Gut Damage
-
PureTech Founded Entity Vedanta Biosciences Appoints Simona Levi as Chief Legal Officer and Corporate Secretary
-
PureTech Health (PRTC) Entity Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA
-
PureTech Founded Entity Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA
-
PureTech Founded Entity Sonde Health Launches Vocal Biomarker Technology to Monitor Mental Health and Well-Being
-
PureTech Founded Entity Akili Announces Topline Results from Shionogi Phase 2 Study in Japan
-
PureTech (PRTC) Announces Publication of New Preclinical Research from Collaborators that Supports Mesenteric Lymphatic Dysfunction as Potential Cause of and Therapeutic Target for Obesity and Insulin
-
PureTech Announces Publication of New Preclinical Research from Collaborators that Supports Mesenteric Lymphatic Dysfunction as a Potential Cause of and Therapeutic Target for Obesity and Insulin Resi
-
PureTech to Present at Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
-
PureTech Health Plc's (PRTC) Vor Biopharma (VOR) Announces VOR33 Granted U.S. FDA Fast Track Designation for Acute Myeloid Leukemia
-
PureTech Founded Entity Vor Biopharma Announces VOR33 Granted U.S. FDA Fast Track Designation for Acute Myeloid Leukemia
-
PureTech Health plc – Half-Year Report
-
PureTech Presents Phase 1 Data for LYT-100 at the European Respiratory Society International Congress 2021
-
PureTech Founded Entity Akili Enters Strategic Licensing Agreement with TALi, Extending Akili Portfolio and Industry Leadership in Prescription Digital Therapeutics for Cognitive Impairments
-
PureTech Announces the Appointment Julie Krop, M.D., as Chief Medical Officer
-
PureTech Announces That Imbrium Therapeutics Has Exercised License Option to LYT-503/IMB-150 for Interstitial Cystitis/Bladder Pain Syndrome
-
PureTech: Notice of Half-Yearly Results
-
PureTech Founded Entity Akili Releases New Gameplay Features in the First and Only FDA-Cleared Video Game Treatment for Children With ADHD
-
PureTech Founded Entity Vedanta Biosciences Completes $68 Million Series D Financing
-
PureTech Founded Entity Gelesis, the Maker of Plenity®, to Become a Publicly Traded Company via Merger with Capstar Special Purpose Acquisition Corp.
-
PureTech Founded Entity Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined with a Bi-Specific Antibody Therapy for Acute Myeloid Leuk
-
PureTech Founded Entity Sonde Health Announces Collaboration with Qualcomm Technologies for Use of Vocal Biomarker Technology on Qualcomm Snapdragon Mobile Platforms
-
PureTech (PRTC) Announces Clinical Trial and Supply Agreement with BeiGene (BGNE) to Evaluate LYT-200 and Tislelizumab in Patients with Difficult-to-Treat Solid Tumors
-
PureTech Announces Clinical Trial and Supply Agreement with BeiGene to Evaluate LYT-200 and Tislelizumab in Patients with Difficult-to-Treat Solid Tumors
-
PureTech Founded Entity Vedanta Biosciences Announces New Data from Phase 1 Study of VE202 for the Treatment of Inflammatory Bowel Disease
-
PureTech Founded Entity Karuna Therapeutics Announces Results from Phase 1b Trial Evaluating the Safety and Tolerability of KarXT in Healthy Elderly Volunteers
-
PureTech Health Plc (PRTC) Acquires Remaining Interest in Founded Entity Alivio Therapeutics
-
PureTech Acquires Remaining Interest in Founded Entity Alivio Therapeutics
-
Results of Annual General Meeting
-
PureTech Founded Entity Gelesis Presents Findings on Plenity®-Induced Weight Loss at the American Association of Clinical Endocrinology (AACE) 2021 Annual Virtual Meeting
-
PureTech (PRTC) Founded Entity Akili Secures $160 Million in Financing
-
PureTech Founded Entity Akili Secures $160 Million in Financing; Poised to Deliver on the Promise of Digital Therapeutics
-
PureTech to Present at the Jefferies Virtual Healthcare Conference
-
PureTech Forms Clinical Advisory Board for Idiopathic Pulmonary Fibrosis and Related Lung Disorders
-
PureTech Announces Nature Publication Supporting Modulation of Meningeal Lymphatics to Target Alzheimer’s Disease Pathologies
-
PureTech Health Plc (PRTC) Adds Jane Wildman to Board
-
PureTech Founded Entity Gelesis Appoints Procter & Gamble Veteran Jane Wildman to Board of Directors
-
PureTech Announces Annual Results for Year Ended December 31, 2020
-
PureTech Health Plc (PRTC)
-
PureTech Presents Promising Preclinical Data from LYT-210 Immuno-Oncology Program at American Association for Cancer Research (AACR) Annual Meeting
-
PureTech to Present at Two Upcoming Investor Conferences

